The Problem — Tagging Humans Like Animals:

Children, babies, pregnant women, elderly, and especially veterans are being injected with gene-based, mRNA-coded biologics (like Moderna's RSV vaccine) without full disclosure of long-term risks, ethical implications, or their role in a broader surveillance infrastructure.

Verification Notes:

As of 2025, the most up-to-date VA documentation (e.g. facility notices and formulary listings) still only reference Abrysvo (Pfizer protein-subunit vaccine), not Moderna's mRNA vaccine.

Yet, there is concrete evidence that the VA (Veterans Health Administration) does stock and has contracted for Moderna's mRNA-based RSV vaccine, mRESVIA (mRNA-1345). Let's cover the facts.

1. Moderna's mRNA-based RSV vaccine

mRNA-1345 (mRESVIA)

https://www.vendorportal.ecms.va.gov/NAC/Pharma/List?Sort=1&TxtNDC=&cboContractNumbers=&cboContractorNames=&cboVAClass=&search=Search&txtCriteria1=RSV+Vaccine&txtPackage

https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/moderna-receives-expanded-approval-rsv-vaccine

2. Genotoxicity / Reverse Transcription Risks of mRNA

It is a genetic instruction system—a software update for your body that reprograms cells to produce proteins (like viral spike or fusion proteins). It's functionally closer to gene therapy than a traditional vaccine.

- Studies (including from Sweden's Lund University) show that mRNA may reverse-transcribe into DNA in certain cell types.Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

https://www.mdpi.com/1467-3045/44/3/73

3. mRNA carries significant risks.

The patent for a delivery lipid nano particle that encodes for the protein of Sars Cov2, within C19 mRNA vaccines showed a substance that may be the cause of health complications. This substance is within **Moderna as SM -102**, and **ALC-0315 from Acuitas Therapeutics in the BioNTech/Pfizer vaccine.**

Per the patent for the particle, it self-assembles in the presence of 5g, and strangely was tested for its capabilities prior to the initial provisional filing 11/27/2019. (See image on blog from 5/9/2024.How did they test both Sars CoV2 and Swabs Before the Pandemic?
https://almscodex.org/health-research-topics/f/how-did-they-test-both-sars-cov2-and-swabs-before-the-pandemic

If one simply looks for the patent on Google they will see a formal filing dated 11/27/20. Expansion of the filing shows the original date. Bing US20210262941A1 - Multipartite luciferase

peptides and polypeptides , Duck Duck Go US20210262941A1 - Multipartite luciferase peptides and polypeptides - Google . It has been buried for unknown reasons several times so we printed it and screen shot our concerns.

 **Sadly, the patent filing demonstrates that it was already tested as an envelope for SARS Cov2, and upon swabs prior to the pandemic. **

US 20210262941A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0262941 A1**

Kincaid et al. (43) **Pub. Date: Aug. 26, 2021**

(54) **MULTIPARTITE LUCIFERASE PEPTIDES AND POLYPEPTIDES**

(71) Applicant: **Promega Corporation**, Madison, WI (US)

(72) Inventors: **Virginia Kincaid**, Madison, WI (US); **Lance P. Encell**, Madison, WI (US); **Mary Hall**, Madison, WI (US); **Michael Killoran**, Madison, WI (US); **Keith Wood**, Madison, WI (US); **Melanie Dart**, Madison, WI (US); **Trish Hoang**, Madison, WI (US)

(21) Appl. No.: **17/105,925**

(22) Filed: **Nov. 27, 2020**

Related U.S. Application Data

(60) Provisional application No. 62/941,255, filed on Nov. 27, 2019.

Publication Classification

(51) **Int. Cl.**

G01N 21/76	(2006.01)
C12N 9/02	(2006.01)
G01N 33/58	(2006.01)

(52) **U.S. Cl.**

CPC ***G01N 21/763*** (2013.01); ***G01N 33/582*** (2013.01); ***C12N 9/0069*** (2013.01)

(57) **ABSTRACT**

Provided herein are bioluminescent polypeptides and compositions and methods for the assembly of a tripartite or multipartite bioluminescent complex. In particular embodiments, a bioluminescent complex is formed upon the interaction of three or more peptide and/or polypeptide components.

Specification includes a Sequence Listing.



SARS-CoV-2 Nucleocapsid Titration

[0766]

Anti-nucleocapsid Ab clone 9547 (Meridian Biosciences) and anti-nucleocapsid Ab clone 9548 (Meridian Biosciences) were labeled with HaloTag®-SmTrip9(pep840) and HaloTag®-VSHiBiT, respectfully. 25 ul/well of a 4× cocktail of Abs+LgTrip ATG-5146 was added to wells of a non-binding surface, solid white 96 well microtiter plate (Costar 3600) for a final concentration/well of 30 ng/ml Ab-SmTrip9+60 ng/ml Ab-HiBiT+1 uM LgTrip ATG-5146. 25 ul/well of a 4× solution of recombinant nucleocapsid protein (Meridian Biosciences Cat # 9560) was added to each well followed by the addition of 50 ul/well of a 2× solution of NanoGlo® Live Cell Substrate for final concentration/well of 10 uM substrate. Plates were incubate for 15 minutes, and total luminescence measured on GlowMax luminometer.

[0767]

FIG. 215 demonstrates ternary NanoLuc®-labeled antibodies detect SARS-CoV-2 Nucleocapsid protein.

EXAMPLE 139Point of Care Swabs for SARS-CoV-2 Nucleocapsid Protein in Nasopharyngeal Swab Samples

[0768]

A stock solution containing 120 ng/ml Anti-nucleocapsid antibody HaloTag®-SmTrip9, 240 ng/ml Anti-nucleocapsid antibody HaloTag®-HiBiT, 4 uM LgTrip ATG-5146, 40 uM Furimazine in ethanol, 1.2 mM azo-thiothymine (ATT), 1.2 mM ascorbic acid, 0.6% pullulan w/v, 4.8 mM HEPES buffer pH 8.0, 21.6 mM Glycine, 4.8 mM histidine, 6 mg/ml sucrose, and 0.0024% Polysorbate 80 was created. 100 ul of the stock solution was dispensed into plastic swab jackets and loaded onto the lyophilizer (Virtis Genesis 12EL) with shelves pre-set to 4.0° C. Upon evacuation of the system, the lyophilization process was performed between shelf temperatures of −25° C. and +25° C. The ice sublimation phase lasted 8 hr, and the bound water desorption phase lasted 16 hr. At the end of the lyophilization process, the swabs were back filled with N° and sealed by inserting a second plastic swab jacket manually.

[0769]

Swabs containing the lyophilized assay reagents were then rehydrated with 100 ul of nasopharyngeal swab samples +300 ul PBS containing 0.01% BSA. Total luminescence was measured on a handheld luminometer (Prom4ega) at times 15, 30, 45, and 60 minutes and plotted.

[0770]

FIG. 216 show the results from 3 PCR confirmed negative (NS46, NS47, and NS52) and 3 PCR confirmed positive samples (PS46, PS49, and PS56).

*The LNP penetrates the eukaryotes. (Cell nucleus)

SM102/ALC-0315 is the key ingredient in both vaccines, in addition to the PEG which is specifically unpleasant:
https://cen.acs.org/pharmaceuticals/drug-delivery/Without-lipid-shells-mRNA-vaccines/99/i8
More about the specific ingredients exposed, but now hidden:
https://www.uchealth.com/en/media-room/covid-19/a-comprehensive-list-of-all-covid-19-vaccine-ingredients
Moderna court case against Pfizer for using their particle, so it is a similar substance:
https://htv-prod-media.s3.amazonaws.com/files/01-main-1661517480.pdf
Both mRNA vaccines use the substance under different names, so we researched the origins of little transgenic particles to discover where they are from. The particle in question appears to originate with Bacmam and/or CRISPR technologies: 📷
Why is this important?
Role in **mRNA Vaccine Development**:

- Baculovirus systems were used in the formulation and development phases to produce components needed for many of the **mRNA vaccines**. These components include enzymes required for **mRNA** synthesis or proteins that can be studied to design better LNP formulations.
Baculovirus in LNP Research:
- In the context of LNP research, baculoviruses are most often used in studies that explore how proteins, peptides, or genetic material can be efficiently packaged into lipid nanoparticles for delivery to specific cells. This substance mixed into the biosynthetic mycobacterium allows for the encoding of things such as luciferase used for tracking what cells have been transfected. In the lab, a substrate called luciferin interacts with say, a swab from a nose and lights up. Probes, such as UV light, can detect transfection as well.
In summary, baculoviruses are primarily used in the production of proteins or genetic material that may later be encapsulated in lipid nanoparticles. Baculoviruses can be engineered to express a wide range of payloads, including proteins, peptides, or other gene therapy molecules. These expressed products can then be encapsulated within various delivery systems, such as **graphene-ferritin
4. Significant Health Risks per FDA Include:

Pfizer adverse reactions released to FDA Analysis: FDA-CBER-2021-5683-0000055
Appendix in the back shows **9 pages of *adverse reactions***
https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pd

- **42 variations of Herpes (micro and macro ulcerations/lesions)**
- **Myocarditis**
- **Blood clots**
- **Neurological disorders**
- **Autoimmune issues**
- **Potential reverse transcription into DNA (undermining the "it doesn't change your genome" claim)**
- **1P36 gene deletion is mentioned first**

There are **thousands of studies** and articles that are posted here and only accessible through DuckDuckGo:
https://docs.google.com/spreadsheets/u/0/d/1-emVRZk7K6iXOGu2Iu0RucLXocEDwJkaojGa5lMhHLU/htmlview

5. More mRNA is being administered to veterans—without clear informed consent.

The VA has procured and deployed Moderna's mRESVIA (an mRNA RSV vaccine).

- Many veterans think they are receiving a routine shot, not a gene-coded biologic.

6. Confirmed Documentation:

- VA mRESVIA Procurement

https://www.vendorportal.ecms.va.gov/NAC/Pharma/List?Sort=1&TxtNDC=&cboContractNumbers=&cboContractorNames=&cboVAClass=&search=Search&txtCriteria1=RSV+Vaccine&txtPackage

- CDC RSV mRNA Clinical Guidance

https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html

- FDA Approval – mRNA-1345

https://products.modernatx.com/mresvia

- VA Clinical Reminder Update Guide

https://www.va.gov/vdl/documents/Clinical/CPRS-Clinical_Reminder_Updates/Update_2_0_394B_IG-508.pdf

- Peer-reviewed safety data

https://academic.oup.com/jid/article/230/3/e637/7595547

7. Interpretation

Yes, the VA has officially procured Moderna's mRNA RSV vaccine (mRESVIA).

Yes, the vaccine is FDA-approved and allowed under CDC/ACIP guidance for certain adult age groups.

VA internal communications or facility brochures may lag in updating which specific RSV platform is offered—especially if mRESVIA adoption began after earlier documents were issued.

Thus, while earlier VA pages mentioned only protein-based RSV vaccines, the procurement data confirms mRESVIA is now part of the VA formulary.

8. It is part of a larger shift toward bio-cyber convergence.

mRNA-based injections act as the first node in a larger network:

Wireless Body Area Networks (WBANs)
Wireless Body Area Networks and Their Applications—A Review | IEEE Journals & Magazine | IEEE Xplore

- https://ieeexplore.ieee.org/document/10024829
- Body area network - Wikipedia
- https://en.wikipedia.org/wiki/Body_area_network

Behavioral surveillance

Digital ID tracking linked to health data

9. Genotoxicity / Reverse Transcription Risks:
There is no off switch.

- Once mRNA instructions are injected and taken up by cells, the body becomes the production site. You can't "recall" the code once it's in.
- Studies (including from Sweden's Lund University) show that mRNA may reverse-transcribe into DNA in certain cell types.
- Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

https://www.mdpi.com/1467-3045/44/3/73
This violates the core promise of "non-integrating" gene therapy platforms.

10. Bio-cyber interface:
Intra-body nano-network - Brief summary by Mik Andersen.pdf | DocDroid (Image Power Point Presentation)
https://www.docdroid.net/tvx0R9b/intra-body-nano-network-brief-summary-by-mik-andersen-pd
11. Childhood Vaccine Schedule Shifts and Those Recommendations to Certain Populations

- There is credible concern that:

All vaccines are being reformulated using mRNA and gene-based delivery systems under the guise of "platform harmonization."

The FDA's new fast-track approval pathways (including "platform-based approvals") allow vaccines (which are now actually gene therapies relabeled if using mRNA)to skip traditional safety trials since they use an "already-approved platform"—like mRNA.

- Informed consent is being sidestepped: many people don't know they are allowing experimental genetic material into their children's developing systems and that of their own bodies.
- ***A call to pediatricians:***

Bihttps://almscodex.org/health-research-topics/f/bio-cyber-pediatrics-vaccines-as-interfaceo-cyber Pediatrics: Vaccines as Interface

Bottom Line:

All people and especially veterans are being turned into testbeds for platform-based genetic programming—with minimal transparency and virtually no recourse. What's marketed as helpful is, in reality, a Trojan horse for an irreversible biological interface.
mRNA vaccines are no normal platform for several reasons. Here we explain what the intention behind the injections and platform truly delivers once the ban on information is removed from the general public.
Bio-cyber interfaces—technologies that enable direct interaction between biological systems (typically the human body or brain) and cyber systems (computers or digital networks). They also introduce a range of significant risks that span across health, privacy, and sociopolitical domains. Below is a detailed exploration of the intended system for the new **precision healthcare model/ecosystem** along with the known risks exposed within the 9 page addendum at the back of the Cumulative Analysis of the Pfizer Vaccine performed and released by the FDA, February 2021.

12. The Bigger Picture: Bio-Digital Convergence/C-19 Vaccines/ISO 20022
mRNA vaccines are no longer just about "immunity"—they are the first widespread biologic interface to reprogram the human body at the molecular level.
Think of mRNACov-19 as Phase One in a larger shift toward programmable biology.

This fits hand-in-glove with:

- **Wireless Body Area Networks (WBANs)**
- **Digital identity linked to health records**
- **Behavioral scoring and predictive health**
- **Net Centric Warfare = ISO 20022 = Hyper Ledger = Blockchain**

https://almscodex.org/health-research-topics/f/net-centric-warfare-iso-20022-hyper-ledger-blockchain

If every adult and child becomes “node-ready” through repeated genetic injections, the biological part of the surveillance network is essentially complete.

A Call to Discernment

“Be sober, be vigilant; because your adversary the devil walks about like a roaring lion, seeking whom he may devour.”
— 1 Kepha (Peter) 5:8, Hebrew Cepher

Final Thoughts…

Here are official VA documents and resources that explicitly mention mRESVIA (Moderna’s mRNA RSV vaccine) by name, and related procedural/internal references. These can serve as evidence that the VA has formally assessed and integrated the vaccine into its system:

- VA Pharmacy Benefits Management Mini-Monograph: Respiratory Syncytial Virus Vaccine (MRESVIA)
- This August 2024 monograph is issued by the VA Pharmacy Benefits Management Services in coordination with the Medical Advisory Panel. It identifies MRESVIA as a modified mRNA RSV vaccine containing the prefusion F protein, approved by FDA on May 31, 2024, for adults aged 60+ .
- VA Formulary Advisor Online Entry: RSV Vaccine (MRESVIA)
- The VA’s official Formulary Advisor lists RSV VACCINE INJ, SUSP (also known as MRESVIA) under its drug detail pages. The listing shows it in the VA national formulary with the generic identifier and acknowledges Moderna as the manufacturer—confirming VA is tracking and approving it for procurement and use .
- VA Clinical Reminder Update Guide: RSV Reminder Dialogs Include Moderna Option A VA-IT install guide dated January 2025 outlines updates to clinical reminders in the electronic medical record system. It includes groups and dialog options for “VAL-GP RESPIRATORY SYNCYTIAL VIRUS ADMINISTER TODAY MODERNA” and refusal options as well—demonstrating internal system support for Moderna’s vaccine alongside Pfizer and GSK products.

How to Find More via FOIA or Internal Notices

If you pursue Freedom of Information Act (FOIA) or internal disclosures, here are steps and resources:

Submit a FOIA request to the Veterans Health Administration (VHA)—direct your request to records concerning mRESVIA procurement, rollout memos, directives, or training materials. Use the VHA FOIA contact email: VHAFOIARequests@va.gov .

To obtain internal or dated documents (like VISN-level memos or rollout schedules), specify records between May 2024 and present, referencing the time around FDA approval and formulary inclusion.

Naysayer Corner:

https://www.vendorportal.ecms.va.gov/NAC/Pharma/List?Sort=1&TxtNDC=&cboContractNumbers=&cboContractorNames=&cboVAClass=&search=Search&txtCriteria1=RSV+Vaccine&txtPackage
https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/moderna-receives-expanded-approval-rsv-vaccine
https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm
https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html
https://www.va.gov/files/2024-09/Viral-Vaccines-HZ_Oct2024_1.pdf
https://products.modernatx.com/mresvia
https://www.cdc.gov/acip/evidence-to-recommendations/mrna-rsv-vaccine-older-adults-etr.html
https://vamedicaid.dmas.virginia.gov/bulletin/vaccinations-available-respiratory-syncytial-virus-season
https://www.nature.com/articles/d41573-024-00095-3
https://arexvy.com/
https://en.m.wikipedia.org/wiki/Respiratory_syncytial_virus_vaccine
https://feeds.issuerdirect.com/news-release.html
https://pubmed.ncbi.nlm.nih.gov/38298125/
https://academic.oup.com/jid/article/230/3/e637/7595547
https://www.pharmacytimes.com/view/study-how-mrna-1345-rsv-vaccine-compares-to-previously-approved-rsv-vaccines
https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/
https://www.cdc.gov/acip/downloads/slides-2024-02-28-29/02-RSV-Adults-Das-508.pdf
https://www.fiercepharma.com/pharma/gsk-confirms-arexvy-blockbuster-says-rsv-battle-has-just-begun
https://www.fda.gov/vaccines-blood-biologics/vaccines/mresvia
https://www.va.gov/formularyadvisor/drugs/4043211-RSV-VACCINE-INJ-SUSP